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Abstract 
Objective: We examined weight changes during chronic hepatitis C (CHC) therapy and associ-
ation with virologic response.  
Methods: Weight changes were compared between subjects achieving rapid, early, and sustained 
virologic response rates (RVR, EVR, and SVR). RVR, EVR and SVR were compared among patients 
with or without weight loss of ≥ 0.5 body mass index (BMI) units (kg/m2) at 4, 12, 48 weeks.  
Results: CHC therapy was initiated in 184 cases. Median pretreatment BMI was 27.7 (18.4-51.3) 
with 38% overweight and 31% obese (BMI ≥25 and ≥ 30, respectively). Among patients with liver 
biopsies (n = 90), steatosis was present in 31.6%; fibrosis grade of 1-2/6 in 46%, 3-4 in 37.3% and 
5-6 in 14.7%. Mean weight loss at 4, 12, 24 and 48 weeks of therapy were 1.2, 2.6, 3.8 and 3.3 kg, 
respectively. After 4 and 12 weeks of treatment, 38% and 54.3% had a BMI decrement of ≥ 0.5 
kg/m2. For genotype 1, weight loss at 4 weeks was associated with significantly higher EVR (90.0% 
vs. 70%, p = 0.01) and a tendency towards better RVR and SVR (42.9% vs. 26.0% and 55.2% vs. 
34.8%, respectively, p = 0.08). In multivariate analysis, weight loss at 4 weeks was independently 
associated with EVR (OR 6.3, p = 0.02) but was not significantly associated with RVR or SVR  
Conclusions: Spontaneous weight loss at 4 and 12 weeks of CHC therapy was associated with 
improved EVR. Weight loss at 4 weeks was an independent predictor of EVR but not SVR. 
Key words: Weight change, hepatitis C, treatment outcomes, virologic response 
Introduction 
An estimated 3% of the world’s population (170+ 
million persons) is infected with the hepatitis C virus 
(HCV) 1, 2. Of those infected, 20% to 50% will develop 
cirrhosis and its related complications 3. The recent 
addition of protease inhibitors has significantly im-
proved the response rate to hepatitis C therapy 4,5. 
However, combination treatment with pegylated IFN 
alpha and Ribavirin remains a critical element in new 
treatment regimens 6 and identifying the predictors of 
viral response may be important in order to optimize 
triple combination therapy 7-9. 
Several factors have been associated with treat-
ment response including virologic and pharmacody-
namic factors in response to interferon based therapy. 
The therapeutic effect of PEG-IFN plus Ribavirin 
therapy is dependent on the rapidity of the virologic 
response. RVR has been shown to predict SVR and is 
strongly associated with treatment response whereby 
patients who achieve RVR have a significantly higher 
chance of achieving SVR 10-12. In addition, pharmaco-
dynamic factors reflected in cytopenias and weight 
loss encountered during therapy have been associated 
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with higher treatment response 13-15. Higher SVR was 
associated with maximum weight loss 13, more than 5 
kg weight loss 14 and with BMI ≤ 27 kg/m2 15 during 
PEG-IFN + Ribavirin therapy of CHC. Alternatively, 
blunted treatment response with less weight loss and 
less cytopenias were independent predictors of null 
response at week 20 of interferon therapy 16. Other 
factors associated with response include genetic fac-
tors such as Interleukin 28B polymorphism 17 patient 
race, age or HCV viral genotype, as well as potentially 
modifiable factors such as obesity and other metabolic 
syndrome components, particularly insulin re-
sistance7.  
Early predictors of treatment response before or 
early after start of therapy have the best chance of 
impacting treatment decisions. In this report, we ex-
amined the extent of weight change during the first 12 
weeks of PEG-IFN + Ribavirin hepatitis C therapy and 
its relation to virologic response. 
Materials and Methods 
Patients 
A retrospective review of electronic medical 
records of treatment-naïve hepatitis C patients with 
chronic hepatitis C confirmed by HCV-RNA referred 
between 2001 and 2009 for hepatitis C management to 
a single tertiary center was conducted. The study was 
approved by the Institutional Review Board (IRB).  
In order to evaluate the effect of early weight loss 
on HCV therapy, patients were categorized into two 
weight loss groups (WL; those whose BMI decreased 
by 0.5 or more kg/m2 from pre-treatment BMI) and 
non-weight loss group (NWL; those whose BMI de-
creased less than 0.5 kg/m2, didn’t change or in-
creased). The cutoff point of 0.5 BMI was chosen as it 
represented the median loss in BMI at 4 weeks for the 
whole study group. Body mass index (BMI) was cal-
culated as weight in kg divided by square meter of the 
height (kg/m2). Overweight or obesity was defined as 
BMI ≥ 25 or ≥ 30, respectively, for both men and 
women. Subjects were considered to have metabolic 
syndrome if they were obese (BMI ≥ 30 kg/m2) in 
addition to 2 or more of the following disorders: 
dyslipidemia, systemic hypertension, and diabetes.  
Data analyzed included sex, race, liver steatosis 
type (micro, macro and mixed steatosis), presence of 
liver steatosis (fat globules involving more than 5% of 
liver parenchyma), percentage of liver parenchyma 
with steatosis, HCV genotype, peg-IFN type (α2a or 
α2b), virologic response rates by PCR, age, weight 
and BMI pre-treatment and at 1, 3, 6 and 48 weeks of 
therapy, treatment duration, pretreatment HCV RNA, 
liver fibrosis grade and pre-treatment ALT and AST. 
Cases with a history of alcohol or drug abuse, other 
etiologies of chronic liver disease or viral co-infection 
with hepatitis B or HIV were excluded. Pre-treatment 
data were used if they were within 3 months preced-
ing the initiation of treatment. Post-treatment varia-
bles were taken at exact time ± 1 month. 
Hepatitis C Therapy 
Hepatitis C therapy consisted of peg-IFN-α2a at 
a dosage of 180 µg/week or 1.5 µg /kg/week for 
peg-IFN-α2b in combination with Ribavirin at a 
weight-based daily oral dose of 800 mg for <65 kg, 
1000 mg for >65-85 kg, 1200 mg for >85-105 and 1400 
mg for >105 kg body weight. Treatment doses were 
adjusted as clinically indicated.5 The completion of 
the HCV therapy course was defined as 80% or more 
of the IFN and Ribavirin doses. Rapid virologic re-
sponse (RVR) was defined as an undetectable serum 
HCV RNA at 4 weeks. Early virologic response (EVR) 
was defined as ≥ 2 log drop of HCV RNA at 12 weeks 
of anti HCV therapy in relation to pretreatment RNA. 
Patients with undetectable virus at the end of treat-
ment and again 24 weeks after completion of treat-
ment were considered to have achieved a sustained 
virologic response (SVR). 
Quantitative assessment of HCV RNA was done 
by in-house quantitative real-time RT-PCR assay, 
(version 2.0; Roche Diagnostics, Branchburg, NJ) and 
HCV genotyping was performed by sequence analysis 
of a portion of the 5`untranslated region of the viral 
genome using Inno-Lipa HCV2 Line Probe Assay 
(Innogenetics, Ghent, Belgium).  
Statistical Analysis 
Data analysis was completed using SPSS for 
Windows, version 17 (SPSS Inc. Chicago, IL). De-
scriptive statistics are presented as mean ± standard 
deviation for quantitative variables and as percent-
ages for qualitative variables. Intent to treat analysis 
was used where data of all patients who received at 
least one dose of hepatitis C therapy was included in 
the analysis. The categorical variables were compared 
with Pearson’s Chi-squared test or Fisher’s Exact test 
as appropriate and, the continuous variables were 
compared with student t-test or Mann Whitney test 
according to the distribution type of data. In order to 
determine independent predictors of HCV response, 
factors significantly associated with virologic re-
sponses by univariate analysis were included in mul-
tivariate logistic regression model. Statistical signifi-
cance was set at p value of 0.05 (two-tailed). 
Results 
Between 2001 and 2009, 438 patients with 
chronic hepatitis C were referred to our center and 
consented to release their information for research 
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purposes (Figure 1). Data were missing in 73 patients; 
256 were treatment-naïve, of whom 184 cases (72 %) 
underwent treatment for Hepatitis C and were in-
cluded in the study population. Hepatitis C therapy 
was not considered in 72 (16%) out of 438 patients. 
The decision not to start treatment was not affected by 
pre-treatment weight or BMI. The percentage of pa-
tients who were not treated was 31.9% and 27.8% for 
normal pre-treatment weight (BMI < 25) and over-
weight/obese (BMI ≥25) subjects, respectively, p = 
0.52. The most common causes of non-treatment were, 
uncontrolled or active psychiatric disorders (n=12), 
alcohol abuse (n=11), decompensated liver disease 
(n=8), and refusal to receive current therapy or pre-
ferring to wait for a new regimen (n=7). Decompen-
sated liver disease was a significantly more common 
cause for non-treatment among patients with BMI ≥ 
25 kg/m2 versus those with BMI < 25 (p = 0.04). Other 
causes for non-treatment were not different among 
the various BMI groups. Out of 184 treatment naïve 
subjects, treatment was discontinued in 37 (20.1%) 
cases due to lack of tolerance and adverse effects as-
sociated with the therapy. The most common of these 
were psychiatric disorders (n=15, 8%), blood cytope-
nia (n=10, 9%), fatigue and eye disorders (n=8, 4%). 
There was no difference in the percentage of patients 
completing 80% or more of therapy among normal 
weight and overweight groups (80% and 78.9%, re-
spectively, p = 0.9). 
 
 
Figure 1: Study flow chart 
Demographics 
Demographic information is summarized in Ta-
ble 1. The mean age was 47.7 ± 11.4 years (range 20.5 - 
71.6) and 106 (57.6%) were males. There were more 
Caucasians n=146 (79.3%) than African Americans n= 
19 (10.3%). The majority of the subjects had HCV 
genotype 1 (n=130, 70.7%) and the remainder had 
type 2 or 3. Pre-treatment body weight was 85.5 kg ± 
21.2 (range 47.1 - 152.8). Overweight and obesity were 
observed in 70 (38%) and 57 (31%), respectively. Liver 
biopsies, available in 90 patients, demonstrated ad-
vanced fibrosis of 4-6/6 in 26 (19.5%) and steatosis in 
37 (31.6%). 
Weight change during hepatitis C therapy 
 The mean weight change at 4 and 12 weeks of 
HCV therapy was -1.2 ± 3.7 and -2.6 ±5.2 kg, respec-
tively (Table 2). Subjects with BMI ≥ 25 lost signifi-
cantly more weight compared to normal weight sub-
jects at all time points (Table 2). Thirty-eight percent 
(n = 70) and 54% (n = 100) had weight loss of 0.5 or 
more kg/m2 compared to pre-treatment BMI, at 4 and 
12 weeks of HCV treatment, respectively (Table 3). 
 Effect of weight loss on virologic responses 
 There was no significant difference in RVR, EVR 
or SV between patients with normal pre-treatment 
weight (BMI < 25) compared with overweight patients 
with pre-treatment BMI ≥ 25 (Table 4).  
Weight change compared to pre-treatment 
weight was compared between patient with 
HCV genotype 1 with and without positive 
RVR, EVR and SVR (Table 5). Patients who 
achieved EVR lost significantly more weight at 4 
and 12 weeks of therapy compared with those 
without EVR. Weight changes at 4, 12, and 48 
weeks of therapy were not significantly differ-
ent between those with or without RVR or SVR 
(Table 5). Virologic response rates were also 
compared between subjects with or without 
weight loss (>0.5 BMI) at 4 and 12 weeks of 
HCV therapy (Table 6). For hepatitis C geno-
type 1, WL group at 4 weeks was associated 
with significantly higher EVR versus NWL 
group (Table 6). The differences in RVR and 
SVR did not reach statistical significance (p = 
0.08). The WL group at 12 weeks of therapy also 
had significantly higher EVR compared to NWL 
group (Table 6). There was no significant dif-
ference in SVR between WL and NWL at 12 
weeks.  
Association of weight loss with virologic 
responses  
Weight loss at 4 and 12 weeks of therapy was 
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associated with EVR. Other factors associated with 
EVR were younger age, non-genotype 1, and lower 
liver fibrosis grade. In multivariate regression analy-
sis, weight loss at 12 weeks remained an independent 
predictor of EVR (OR 6.25, 95% CI 1.3 – 33.3, p = 0.02). 
Weight loss at 4 and 12 weeks was not an independent 
predictor of RVR or SVR (Table 7). 
 
Table 1: Baseline demographic and clinical characteristics of 184 treatment-naïve patients who underwent treatment for chronic hep-
atitis C and were included in the study. 
Variable No (%) 
Number of patient  184 
Mean age in years ± SD, (range) 47.7 ± 11.4 , (20.5-71.6) 
Sex: Male, n (%) 106 (57.6) 
Race: n, (%)  
Caucasian 146 (79.3) 
African American 19 (10.3) 
Oriental 14 (7.6) 
Hispanic 1 (0.54) 
Unknown 4 (2.2) 
HCV Genotype: n, (%)  
1 130 (70.7) 
2 35 (19) 
3 19 (10.3) 
Mean pre-treatment weight (kg) ± SD, (range) 85.5 ± 21.2, (47.1-152.8) 
Median pre-treatment BMI (range) 27.7 (18.4-51.3) 
Metabolic Syndrome: n, (%) 15 (8.2) 
Categories based on pre-treatment BMI (kg/m2), n (%):  
Normal (BMI <25 kg/m2),  49 (26.6) 
Overweight (BMI ≥ 25 and < 30 kg/m2), n (%) 70 (38) 
Obese (BMI ≥ 30 kg/m2), n (%) 57 (31)  
Liver biopsy: n (%)  
Advanced Fibrosis of 4-6/6 26 (19.5) 
Steatosis 37 (31.6) 
Abbreviations: BMI = body mass index; n = number of patients; SD = standard deviation  
 
Table 2: Mean weight changes in kg at different times of PEG-IFN and Ribavirin chronic hepatitis C therapy. 
Categories based on Pre-treatment BMI 
(kg/m2) 
4 weeks 
Mean ± SD 
12 weeks 
Mean ± SD 
24 weeks 
Mean ± SD 
48 weeks 
Mean ± SD 
All patients -1.2 ± 3.7 -2.6 ± 5.2 -3.8 ± 6.7 -3.3 ± 6.6 
< 25, -0.3 ± 2.8 -0.9 ± 4.5 -1.5 ± 5.4 -1.0 ± 7.4 
≥ 25 -1.6 ± 3.9 - 3.3 ± 5.3 -4.7 ± 7.0 -4.3 ± 8.1 
P value 0.03 * 0.00* 0.00* 0.04* 
All comparisons are made with respect to pre-treatment 
P*: significant p value (< 0.05) for BMI < 25 versus ≥25. 
Abbreviations: BMI, body mass index; PEG-IFN, pegylated interferon; m, meter; kg, kilogram. 
 
Table 3: Percentage of subjects who showed weight loss (≥ 0.5 BMI) at different times of chronic hepatitis C treatment.  
Categories based on 
pre-treatment BMI (kg/m2) 
4 weeks 
 
12 weeks 
 
24 weeks 
 
48 weeks 
 
     
All, n (%) 70 (38) 100 (54.3) 99 (58.8) 61 (33.2) 
<25, n (%) 14 (31.1) 23 (48.9) 25 (54.3) 15 (42.9) 
≥25, n (%) 56 (48.7) 77 (64.2) 74 (64.9) 46 (56.8) 
P value 0.04* 0.07 0.21 0.16 
Abbreviations: BMI, body mass index; n, number; m, meter; kg, kilogram. 
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Table 4: Effect of pre treatment BMI on virological responses. 
Pre-treatment BMI 
(kg/m2) 
RVR EVR SVR 
Genotype 1 Genotype 2/3 Genotype 1 Genotype 2/3 Genotype 1 Genotype 2/3 
< 25, n (%) 10 (33.3) 8 (88.9) 31 (88.6) 12 (100) 13 (56.5) 4 (80) 
≥ 25, n (%) 21 (30.9) 26 (92.9) 60/81 
(74.1) 
32/34 
(94.1) 
22/60 
(46.7) 
21/23 
(91.3) 
P value 0.81 1.00 0.08 1.00 0.10 0.45 
Abbreviations: BMI, body mass index; EVR, early virological response; n, number; RVR, rapid virological response; SVR, sustained virological response. 
 
Table 5: Weight changes from pre-treatment weight among subjects with chronic HCV Gen 1 with and without virologic response to 
HCV therapy with PEG-interferon + Ribavirin.  
 RVR EVR SVR 
 Negative Positive Negative Positive Negative Positive 
Pre-treatment Weight  
P value 
83.2 ± 19.9 
 
86.3 ± 18.8 
0.5 
87.0 ± 22.9 85.3 ± 19.8 
0.5 
85.7 ± 21.4 80.1 ± 19.9 
0.5 
Wt change at 4 wks  
P value 
-1.1 ± 0.5 -1.7 ± 0.5 
0.3 
0.3 ± 0.5 1.5 ± 3.8 
0.003 
0.5 ± 3.6 1.3 ± 3.6 
0.3 
Wt change at 12 wks  
P value 
  0.9 ± 2.9 2.9 ± 5.5 
0.01 
1.9 ± 4.3 2.4 ± 5.4 
0.3 
Wt change at 48 wks  
P value 
    2.3 ± 6.7 2.1 ± 7.8 
0.9 
P*: significant p value (< 0.05). 
Data are mean + Standard deviation. 
Positive = Pt achieved a positive response to HCV treatment 
RVR = rapid virologic response, EVR = early virologic response and SVR = sustained virologic response 
 
Table 6: Virologic response rates in patients with HCV Genotype 1 with, versus those without, weight loss (BMI decrease by 0.5 or more 
kg/m2 from baseline pre-treatment BMI) at 4 and 12 weeks of PEG-IFN/Ribavirin therapy. 
 RVR EVR SVR 
Weight changes at 4 weeks of HCV therapy 
Weight Loss, n (%) 18 (42.9%) 40 (90.9%) 16 (55.2%) 
No weight loss, n (%) 13 (26.0%) 44 (71.0%) 16 (34.8%) 
P value 0.08 0.01* 0.08 
Weight changes at 12 weeks of HCV therapy 
Weight Loss, n (%)  55 (85.9%) 18 (45%) 
No weight loss, n (%)  34 (70.8)% 15 (38.5%) 
P value  0.049* 0.55 
P*: significant p value (< 0.05). 
Abbreviations: BMI, body mass index; EVR, early virologic response; NA, non-applicable; RVR, rapid virologic response; SVR, sustained virologic response; WL, weight loss. 
RVR = rapid virologic response, EVR = early virologic response and SVR = sustained virologic response 
 
Table 7: Factors independently associated with virologic responses. All factors that were significantly associated with virologic responses 
by univariate correlation analysis were included in the multivariate regression analysis. 
 Factor OR 95% CI P value 
RVR Age 0.963 0.91 - 1.02 0.21 
Non genotype 1 HCV 19.031 3.90 - 92.98 0.00* 
Pre-treatment HCV RNA load 1.00 1.00 - 1.00 0.11 
Pre treatment ALT 6.25 1.3 - 33.3 0.02* 
EVR Age 0.975 0.91 - 1.04 0.45 
Non genotype 1 HCV 8.906 0.98 - 81.02 0.05* 
Weight loss at 4 wks 0.160 0.03 - 0 .77 0.02* 
Weight loss at 12 wks 1.23 0.335 - 4.5 0.75 
Liver fibrosis grade 0.749 0.48 - 1.15 0.18 
SVR Non genotype 1 HCV 15.152 3.394 - 67.642 0.00* 
Age 0.921 0.869 - 0.976 0.01* 
P*: significant p value (< 0.05). 
Abbreviations: CI, confidence interval; OR, odds ratio.  
RVR = rapid virologic response, EVR = early virologic response and SVR = sustained virologic response. 
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Discussion 
Several studies have demonstrated that weight 
loss observed during hepatitis C Interferon based 
therapy is associated with response to therapy 13-15. 
Chung et al demonstrated a relation between maxi-
mum weight loss during therapy and treatment re-
sponse (SVR, Relapse or breakthrough) versus 
non-responders. However, there was no weight loss 
between those with or without SVR13. On the other 
hand, Suwantarat et al demonstrated that weight loss 
of more than 5 kg at end of treatment was an inde-
pendent predictor of SVR14. The timing of weight loss 
during HCV therapy and the relationship between 
early weight changes during the first 12 weeks of 
therapy and rapid and early virologic responses may 
be most valuable in optimizing treatment decisions. In 
addition, rapid and early virologic responses at 4 and 
12 weeks of therapy are of great significance in pre-
dicting SVR 4,5,10-12 and determining the length of 
therapy in triple combination therapy4,5. The main 
objective of this study was to evaluate the relationship 
of spontaneous weight loss at different times of 
PEG-IFN plus Ribavirin therapy on treatment re-
sponse. 
In our study, overweight subjects at the start of 
therapy lost significantly more weight compared to 
subjects with normal weight. A similar observation 
was previously reported although not with statistical 
significance18. Our data indicate that among patients 
with HCV genotype 1, spontaneous weight loss of ≥ 
0.5 kg/m2 at 4 and 12 weeks of PEG-IFN + Ribavirin 
therapy was associated with significantly higher EVR. 
In addition, after adjusting for other factors associated 
with EVR, weight loss at 4 weeks continued to be an 
independent predictor of achieving a positive EVR. 
Although not statistically significant, patients with 
weight loss at 4 weeks tended to have higher RVR and 
SVR versus patients without such weight loss. The 
mechanism of weight loss in PEG IFN + Ribavirin 
therapy is not well established. Loss of appetite and 
nausea are commonly encountered during HCV 
therapy. Changes in insulin, leptin and proinflam-
matory cytokines have been implicated18. Fioravante 
et al demonstrated that the weight loss during treat-
ment was accompanied by a significant decrease in 
energy intake as assessed by 24-h recall. However, 
there was no change in resting energy expenditure19.  
Several studies have shown obesity as a risk 
factor for non-response to IFN- based hepatitis C 
treatment. Obesity as indicated by body weight above 
75 kg 7, body surface area above 2 meter square 17, and 
BMI ≥ 30 (kg/m2), 20,21 was an independent predictor 
of non-response to IFN- based HCV therapy. In our 
study, patients with normal pre-treatment BMI tend-
ed to have higher EVR and RVR compared to those 
with overweight or obesity with BMI ≥ 25 although 
these differences were not statistically significant. 
Other studies did not demonstrate a relationship be-
tween pre-treatment BMI and virologic response. For 
example, Zeuzem et al reported a negative effect of 
obesity as defined by surface area but not by weight 
or BMI 17.  
Our study is limited by its retrospective design. 
Most of our patients were Caucasians (79%) with Af-
rican Americans constituting only 10%. This may 
partially explain the higher rate of RVR and EVR in 
our study compared to previously reported rates. 
Conclusion  
In conclusion, spontaneous weight loss at 4 and 
12 weeks of CHC therapy was associated with im-
proved EVR and weight loss at 4 weeks was an inde-
pendent predictor of EVR. However, weight loss at 4 
and 12 weeks of therapy was not a predictor of SVR.  
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